💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Ex-drug executive Shkreli hires lawyer to celebrities for fraud case

Published 02/02/2016, 12:05 PM
Updated 02/02/2016, 12:10 PM
© Reuters. Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn in New York
TVTX
-

By Nate Raymond

NEW YORK (Reuters) - Former drug executive Martin Shkreli, facing an indictment for engaging in securities fraud, replaced his legal team on Tuesday with a New York lawyer whose past clients have included former International Monetary Fund chief Dominique Strauss-Kahn and rapper Sean "Diddy" Combs.

Shkreli, 32, had gained notoriety before his indictment when Turing Pharmaceuticals, which he headed at the time, raised the price of a drug used to treat a dangerous parasitic infection to $750 from $13.50.

The lawyer, Benjamin Brafman, confirmed on Tuesday that he had been hired to represent Shkreli, who was arrested in December on charges filed in federal court in Brooklyn, New York.

"We are confident that he will be fully exonerated," Brafman said in a statement. "It is clear that Mr. Shkreli never intended to violate the law, nor did he ever intend to defraud anyone."

Shkreli, during an interview on Fox Business Network on Tuesday, said he was "excited" about hiring Brafman, whose clients have also included rock star Michael Jackson, football player Plaxico Burress and rapper Jay-Z.

"You know, his track record is impeccable, and I think that to the extent that he's representing me going forward, I think we're going to put our best foot forward," Shkreli said.

The criminal charges against Shkreli stem from his prior management of hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc (O:RTRX).

Prosecutors said Shkreli had engaged in a Ponzi-like scheme, defrauding investors in MSMB and misappropriating $11 million in assets from Retrophin to repay them.

Shkreli, who has pleaded not guilty, had previously been represented in the case by law firm Arnold & Porter, but last month disclosed he planned to hire new legal counsel.

He is scheduled to appear in court on Wednesday, the day before he is expected to appear at a congressional hearing on drug pricing and assert his Fifth Amendment right against self-incrimination under the U.S. Constitution.

Brafman in 2001 secured the acquittal of Combs on gun and bribery charges stemming from a shooting in a New York nightclub.

He later represented Strauss-Kahn in 2011 in a sexual assault case involving a hotel maid. The charges were dropped later that year at the prosecution's request amid questions about the maid's credibility.

© Reuters. Shkreli, chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs U.S. Federal Court after an arraignment following his being charged in a federal indictment filed in Brooklyn in New York

Brafman currently is representing Macau billionaire Ng Lap Seng against federal charges that he bribed former United Nations General Assembly President John Ashe.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.